Consolidated Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 13,055,558	$ 20,637,045
Short-term investment securities	14,177,441	8,457,452
Interest receivable	157,201	112,247
Accounts receivable	384,963	294,199
Prepaid expenses and other current assets	216,189	280,555
Total current assets	27,991,352	29,781,498
Non-current assets:
Investment in Alphazyme	284,709	284,709
Other assets	6,151	6,225
Total assets	28,282,212	30,072,432
Current liabilities:
Accounts payable	1,473,813	1,013,099
Accrued expenses	277,668	489,756
Deferred research and development obligations	842,248	123,016
Total current liabilities	2,593,729	1,625,871
Commitments and contingencies (Note 4)
Stockholders’ equity:
Preferred stock, $.0001 par value: Authorized shares - 5,000,000; none issued and outstanding	0	0
Common stock, $.001 par value: Authorized shares - 100,000,000; issued shares - 39,807,659 and 39,747,659, outstanding shares - 27,554,157 and 27,494,157 as of March 31, 2021 and December 31, 2020, respectively	39,808	39,748
Additional paid-in capital	98,549,890	98,013,079
Treasury stock, shares held at cost - 12,253,502	(18,929,915)	(18,929,915)
Accumulated deficit	(53,971,300)	(50,676,351)
Total stockholders’ equity	25,688,483	28,446,561
Total liabilities and stockholders’ equity	$ 28,282,212	$ 30,072,432

Represents the current amount of prepaid research and development in process as of the balance sheet date.

No definition available.

Name:	dyai_PrepaidResearchAndDevelopmentInProcessCurrent
Namespace Prefix:	dyai_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).